InMode’s (INMD) Hold Rating Reaffirmed at Needham & Company LLC

Needham & Company LLC reiterated their hold rating on shares of InMode (NASDAQ:INMD) in a report published on Thursday morning, Benzinga reports.

Separately, Barclays dropped their price objective on shares of InMode from $34.00 to $33.00 and set an overweight rating for the company in a report on Friday, April 12th. Four equities research analysts have rated the stock with a hold rating and two have assigned a buy rating to the company’s stock. Based on data from MarketBeat, the stock has an average rating of Hold and a consensus target price of $31.60.

InMode Stock Performance

InMode stock opened at $17.87 on Thursday. The company’s 50 day simple moving average is $18.25 and its 200-day simple moving average is $20.17. The company has a market capitalization of $1.50 billion, a price-to-earnings ratio of 8.47 and a beta of 2.18. InMode has a 1 year low of $16.44 and a 1 year high of $48.25.

InMode (NASDAQ:INMD) last released its quarterly earnings results on Thursday, May 2nd. The healthcare company reported $0.41 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $0.32 by $0.09. The business had revenue of $80.28 million for the quarter, compared to the consensus estimate of $80.10 million. InMode had a net margin of 38.84% and a return on equity of 26.15%. Equities analysts expect that InMode will post 1.8 earnings per share for the current year.

Institutional Inflows and Outflows

Institutional investors and hedge funds have recently added to or reduced their stakes in the company. Principal Securities Inc. acquired a new position in InMode during the 4th quarter worth approximately $32,000. Sunbelt Securities Inc. acquired a new position in InMode during the 3rd quarter worth approximately $47,000. Headlands Technologies LLC grew its holdings in InMode by 118.2% during the 1st quarter. Headlands Technologies LLC now owns 1,916 shares of the healthcare company’s stock worth $41,000 after acquiring an additional 1,038 shares in the last quarter. Trust Co. of Vermont grew its holdings in InMode by 32.8% during the 4th quarter. Trust Co. of Vermont now owns 2,168 shares of the healthcare company’s stock worth $48,000 after acquiring an additional 536 shares in the last quarter. Finally, Newbridge Financial Services Group Inc. grew its holdings in InMode by 69.2% during the 4th quarter. Newbridge Financial Services Group Inc. now owns 2,200 shares of the healthcare company’s stock worth $49,000 after acquiring an additional 900 shares in the last quarter. Institutional investors and hedge funds own 68.04% of the company’s stock.

InMode Company Profile

InMode Ltd. designs, develops, manufactures, and markets minimally invasive aesthetic medical products based on its proprietary radiofrequency assisted lipolysis and deep subdermal fractional radiofrequency technologies in the United States and internationally. The company offers minimally invasive aesthetic medical products for various procedures, such as liposuction with simultaneous skin tightening, body and face contouring, and ablative skin rejuvenation treatments, as well as for use in women's health conditions and procedures.